ProPhase Labs, Inc. (PRPH): Price and Financial Metrics
Today's Latest Price: $1.46 USD
Jul 8 6:55pm Add PRPH to Watchlist Sign Up PRPH Stock Summary PRPH has a higher market value than just 7.95% of US stocks; more precisely, its current market capitalization is $16,923,806. The ratio of debt to operating expenses for ProPhase Labs Inc is higher than it is for about only 0.34% of US stocks. PRPH's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 8.78% of US stocks. If you're looking for stocks that are quantitatively similar to ProPhase Labs Inc, a group of peers worth examining would be TC, CDXC, USLM, ESP, and PCYO. PRPH's SEC filings can be seen here. And to visit ProPhase Labs Inc's official web site, go to www.prophaselabs.com. PRPH Price/Volume Stats
PRPH Latest News Stream
All News Types
Event/Time News Detail Loading, please wait... Latest PRPH News From Around the Web
Below are the latest news stories about ProPhase Labs Inc that investors may wish to consider to help them evaluate PRPH as an investment opportunity.
DOYLESTOWN, Pennsylvania, May 12, 2020 -- ProPhase Labs, Inc. (NASDAQ: PRPH, www.ProPhaseLabs.com) today announced net sales of $1.9 million for the three months ended March.
Anyone interested in ProPhase Labs, Inc. (NASDAQ:PRPH) should probably be aware that the Chairman & CEO, Ted Karkus...
DOYLESTOWN, Pennsylvania, March 25, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH, www.ProPhaseLabs.com) today announced its net sales were…
Ted Karkus has been the CEO of ProPhase Labs, Inc. (NASDAQ:PRPH) since 2009. This report will, first, examine the CEO...
Monday's massive swoon quickly sent that record into the ash heap of history, as the Dow fell by 2,013 points, or 7.8%, to 23,851, as the continued spread of coronavirus and a potential crude oil price war triggered a required 15-minute halt to trading just four minutes after the market opened. Plymouth Meeting-based Inovio Pharmaceuticals (NASDAQ: INO) had been virtually the region’s sole winner over the past week, as its stock was on a steady ascent since announcing it was accelerating the development of its experimental coronavirus vaccine INO-4800. Wilmington-based chemical manufacturer Chemours Co. (NYSE: CC) fell by 22.8% to $10.40.
Read More 'PRPH' Stories Here
PRPH Price Returns
2.74% Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 1.0475 seconds.